Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments

• Main Authors: Aslı Bilgiç Temel (Author), Cumhur Ibrahim Bassorgun (Author), Ayşe Akman-Karakaş (Author), Erkan Alpsoy (Author), Soner Uzun (Author)
• Format: Book
• Published: Karger Publishers, 2017-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reporte...